BLI International Chlorpheniramine Maleate Recall: Superpotency Triggers FDA Class II Action
BLI International initiated a Class II recall for 4,901 cases of Chlorpheniramine Maleate 4 mg tablets due to superpotency from stability failure. This terminated recall, impacting private label customers in OH and MO, underscores critical quality control challenges. Procurement and regulatory teams must scrutinize supplier stability data to mitigate supply chain and patient safety risks.
FDA Class II Recall: Superpotency Identified in BLI International's Chlorpheniramine Maleate Tablets
On October 21, 2024, BLI International, Inc., based in Deer Park, NY, initiated a voluntary Class II recall for 4,901 cases of Chlorpheniramine Maleate 4 mg tablets, specifically lot # 24A27724 with an expiration date of January 31, 2027. This action, designated recall number D-0029-2025, was prompted by a critical stability failure: the product was found to be superpotent at the 6-month test time-point for assay, meaning the active pharmaceutical ingredient (API) concentration exceeded its specified limits. For procurement directors, this event highlights the imperative of stringent quality assurance protocols throughout the product lifecycle, particularly concerning stability testing. A superpotent drug poses significant risks, as it can lead to unintended adverse effects for patients, directly impacting brand reputation and potentially incurring product liability. Regulatory affairs heads must ensure their internal quality systems are robust enough to detect such deviations early, preventing market distribution of non-compliant products. The FDA officially terminated this recall on December 5, 2025, indicating that BLI International has completed all necessary corrective actions, but the initial failure underscores a fundamental challenge in pharmaceutical manufacturing.
Supply Chain Exposure: Distribution Impact of BLI International's Superpotent Drug Recall
The recalled Chlorpheniramine Maleate 4 mg tablets, packaged in 24-count bottles under NDC 53185-277-24, were distributed as a final packaged product to two private label customers located in Ohio (OH) and Missouri (MO). For supply chain VPs and business development executives, this distribution pattern signifies direct exposure for these unnamed private label partners. These customers would have been responsible for their own brand marketing and sales, now facing potential inventory write-offs, disruption to their sales channels, and reputational damage by association with a superpotent drug. Procurement directors sourcing over-the-counter (OTC) medications must immediately review their supplier contracts and quality agreements, specifically focusing on clauses related to product stability and recall liabilities. The incident emphasizes the need for comprehensive due diligence on contract manufacturers and private label suppliers, extending beyond initial qualification to continuous monitoring of their quality control data and regulatory compliance history. Failure to do so can lead to unforeseen operational costs and market access challenges, particularly in geographically concentrated distribution networks.
Therapeutic Implications: Patient Safety Risks from Superpotent Chlorpheniramine Maleate
Chlorpheniramine Maleate is a commonly used antihistamine for allergy relief. A superpotent formulation, as identified in BLI International's recalled product, carries significant patient safety implications. Increased concentrations of the active ingredient can lead to exaggerated pharmacological effects, such as heightened drowsiness, dizziness, dry mouth, and blurred vision. These effects are particularly concerning for vulnerable populations, including the elderly and children, who may be more susceptible to adverse reactions or accidental overdose. For regulatory affairs heads, this incident underscores the critical importance of maintaining drug potency within established specifications to ensure both efficacy and safety. The commercial impact extends to potential product liability claims, increased pharmacovigilance reporting requirements, and a erosion of consumer trust in OTC medications. Business development executives must consider how such quality failures can impact market perception and future product launches, necessitating robust internal processes to prevent deviations that compromise patient well-being and regulatory standing. The Class II classification by the FDA indicates that while the probability of serious adverse health consequences is remote, it is not negligible.
Mitigating Supply Risk: Strategic Sourcing for Antihistamine APIs and Finished Products
Given the recall of Chlorpheniramine Maleate 4 mg tablets by BLI International, procurement directors must re-evaluate their sourcing strategies for antihistamine APIs and finished drug products. While specific alternative suppliers for Chlorpheniramine Maleate are not detailed in the available intelligence, a proactive approach involves diversifying the supply base to mitigate single-point-of-failure risks. Companies should identify and qualify multiple manufacturers across different geographies, ensuring a resilient supply chain for critical OTC medications. This includes rigorous audits of potential new suppliers' stability testing protocols, quality management systems, and regulatory compliance records. Qualification timelines for new pharmaceutical suppliers can range from 6 to 18 months, necessitating early engagement and strategic planning. Business development executives should explore partnerships with manufacturers demonstrating a consistent track record of FDA compliance and robust quality control. Relying on a single source, or sources with questionable stability data, exposes businesses to significant operational disruptions, inventory stockouts, and potential revenue losses, particularly for high-volume OTC products like antihistamines.
Broader Regulatory Compliance Landscape: Persistent Quality Challenges Across the Industry
The Class II recall of Chlorpheniramine Maleate by BLI International is not an isolated incident but reflects a broader pattern of quality challenges within the pharmaceutical industry, as evidenced by recent parallel events. For instance, Pfizer has faced Class I recalls for Bleomycin Injection and Sodium Bicarbonate Injection due to glass particulate matter, highlighting critical manufacturing control issues. Similarly, Sandoz initiated a Class II recall for Enoxaparin Sodium, and both Teva Pharmaceuticals (Warfarin Sodium) and Allergan (ARMOUR THYROID) experienced Class II recalls linked to Cardinal Healthcare's temperature excursion CGMP deviations. These incidents, ranging from stability failures to particulate contamination and storage deviations, underscore the persistent regulatory scrutiny by the FDA on Good Manufacturing Practices (GMP). Regulatory affairs heads must recognize that robust quality management systems are non-negotiable. Investment in advanced analytical testing, environmental controls, and comprehensive stability programs is crucial. This landscape demands continuous vigilance and proactive remediation strategies to avoid costly recalls, maintain market access, and protect patient safety, which directly impacts a company's financial performance and long-term viability.
Post-Recall Actions and Future Compliance for BLI International
With the FDA's termination of recall D-0029-2025 on December 5, 2025, BLI International, Inc. has formally completed the required actions to address the superpotency issue in its Chlorpheniramine Maleate 4 mg tablets. This termination signifies that the FDA is satisfied with the firm's efforts to remove the affected product from distribution and implement corrective and preventive actions (CAPA). For regulatory affairs heads, understanding the implications of a terminated recall is crucial: it indicates a resolution, but often leads to increased regulatory oversight for the company. BLI International would have been required to conduct a thorough root cause analysis, revise its stability protocols, and potentially upgrade its manufacturing processes to prevent recurrence. Procurement directors and supply chain VPs who partner with BLI International should seek detailed assurances regarding these implemented CAPAs and request updated stability data for future batches. While the immediate crisis is resolved, the incident serves as a reminder for BLI International to maintain heightened vigilance on quality control to avoid future enforcement actions, which could range from further recalls to Warning Letters or even Import Alerts, severely impacting their commercial operations and market standing.